This edition of IASLC Hot Topic in Basic and Translational Science Meeting: Resistance to Immunotherapy has already taken place.
Search future editions →Events › B2B Event
B2B Event
A specialized scientific conference focusing on the biological mechanisms behind primary and acquired resistance to immunotherapy in thoracic oncology. The meeting brings together experts to discuss research in the tumor microenvironment, novel agents, and therapeutic strategies.
Filter this event to your ICP.
Hundreds of exhibitors here. You probably care about 20–30. Tell us your ICP, we'll find them.
Request intelligence →Delivery within 24 hours · $1,250
⚠️ The exhibitor list for this event isn't publicly accessible yet. We'll work on it once you submit a request.
Organizer
International Association for the Study of Lung CancerNonprofit · Denver, United States · Founded 1974
Global professional organization dedicated to the study and eradication of lung cancer and other thoracic malignancies.
Why people attend
Scientists, clinicians, and researchers attend to discuss cutting-edge research, network with experts, and explore new therapeutic strategies to combat immunotherapy resistance in lung cancer
Exhibitor categories
Sample matches
Filtered to a Series-B SaaS ICP. Your filter will be different.
Sample Match A
example.com
"Strong ICP match: Series B, EU expansion, VP Engineering and CTO attending."
Sample Match B
example.io
"Mid-stage SaaS with active GTM motion; product-led growth signals align with ICP."
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
Speakers
3 speakers at IASLC Hot Topic in Basic and Translational Science Meeting: Resistance to Immunotherapy
Chief Scientist · Baptist Memorial Health Care Corporation
"Be Assured, the Dragon Is not Dead: Tobacco Control and the Lung Cancer Population Impact Pyramid"
Director of the Multidisciplinary Thoracic Oncology Program and the Thoracic Oncology Research Group at the Baptist Cancer Center.
Also speaking at IASLC 2027 Asia Conference on Lung Cancer, 2027 Targeted Therapies of Lung Cancer
Professor · Guangdong Provincial People’s Hospital
"Zero Tolerance Strategy to Fight Lung Cancer"
Director of Guangdong Lung Cancer Institute and director of Lung Cancer Specialist Group of Chinese Society of Clinical Oncology.
Also speaking at IASLC Latin America Conference on Lung Cancer, IASLC 2027 Asia Conference on Lung Cancer, 2027 Targeted Therapies of Lung Cancer
Medical Oncologist · Johns Hopkins University
"The Evolution of Neoadjuvant Immunotherapy for Lung Cancer"
Co-director of the Division of Upper Aerodigestive Malignancies in the Department of Oncology at Johns Hopkins University.
Also speaking at IASLC Latin America Conference on Lung Cancer, IASLC 2027 Asia Conference on Lung Cancer, 2027 Targeted Therapies of Lung Cancer
More events in Ireland
Frequently asked questions